7,304 results match your criteria Lymphoma Cutaneous T-Cell


The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas.

Blood 2019 Jan 11. Epub 2019 Jan 11.

Hematopathology section, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, United States.

Primary cutaneous lymphomas are a heterogeneous group of T-cell lymphomas and B-cell lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. In the last decade the 2005 WHO-EORTC consensus classification has served as a golden standard for the diagnosis and classification of these conditions. In September 2018 an updated version of the WHO-EORTC was published in the 4th edition of the WHO classification for Skin Tumours Blue Book. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-11-881268DOI Listing
January 2019
10 Reads

Immunophenotype switching in cutaneous T-cell lymphoma: nature or nurture?

Authors:
Stephen M Ansell

Leuk Lymphoma 2019 Jan 11:1-2. Epub 2019 Jan 11.

a Division of Hematology , Mayo Clinic , Rochester , Minnesota 55905 , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1
Publisher Site
http://dx.doi.org/10.1080/10428194.2018.1543887DOI Listing
January 2019
9 Reads

Molecular alterations in primary cutaneous CD30 lymphoproliferative disorders.

Haematologica 2019 Jan 10. Epub 2019 Jan 10.

Fundacion Jimenez Diaz, CIBERONC.

Primary cutaneous CD30-positive T-cell lymphoproliferative disorders (LPDs) are the second most common subgroup of cutaneous T-cell lymphomas. They include two clinically different entities with some overlapping features and borderline cases, lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large cell lymphoma (pcALCL). Molecular studies of pcALCL reveal an increasing level of heterogeneity that is associated with histological and immunophenotypic features of the cases and their response to specific therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.197152DOI Listing
January 2019

[Single-center retrospective analysis of extracorporal photopheresis in clinical practice : Peripheral venous compared to central venous access].

Hautarzt 2019 Jan 9. Epub 2019 Jan 9.

Klinik für Dermatologie, Venerologie und Allergologie, Universitätsmedizin Mannheim, Ruprecht-Karls-Universität Heidelberg, Mannheim, Deutschland.

Background: Extracorporal photopheresis (ECP) was shown to be effective without severe side effects in the treatment of cutaneous T cell lymphoma (CTCL) and graft versus host disease (GvHD). However, only few studies investigated the practical aspects of ECP.

Methods: Treatment protocols of 2038 ECP procedures in 52 patients (CTCL, n = 29; GvHD, n = 15; other, n = 8) were evaluated. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00105-018-4327-y
Publisher Site
http://dx.doi.org/10.1007/s00105-018-4327-yDOI Listing
January 2019
1 Read

Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma.

JCI Insight 2019 Jan 10;4(1). Epub 2019 Jan 10.

Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Psoralen plus UVA (PUVA) is an effective therapy for mycosis fungoides (MF), the skin-limited variant of cutaneous T cell lymphoma (CTCL). In low-burden patients, PUVA reduced or eradicated malignant T cells and induced clonal expansion of CD8+ T cells associated with malignant T cell depletion. High-burden patients appeared to clinically improve but large numbers of malignant T cells persisted in skin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/jci.insight.124233DOI Listing
January 2019
5 Reads

HER2 CAR-T cells eradicate uveal melanoma and T cell therapy-resistant human melanoma in interleukin-2 (IL-2) transgenic NOD/SCID IL-2 receptor knockout mice.

Cancer Res 2019 Jan 8. Epub 2019 Jan 8.

Sahlgrenska Cancer Center, University of Gothenburg

Chimeric antigen receptors (CAR) can transmit signals akin to those from activated T cell receptors when bound to a cell surface target. CAR expressing T cells against CD19 can cause curative effects in leukemia and lymphoma and is approved for clinical use. However, no CAR-T therapy is currently approved for use in solid tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-3158DOI Listing
January 2019
10 Reads

Measurement of Quality of Life in Patients with Mycosis Fungoides/Sézary Syndrome Cutaneous T-Cell Lymphoma: Development of an Electronic Instrument.

J Med Internet Res 2019 Jan 7;21(1):e11302. Epub 2019 Jan 7.

PatientsLikeMe, Inc, Cambridge, MA, United States.

Background: Although the quality of life (QoL) plays an important role in treatment decision making and clinical management of mycosis fungoides (MF) or Sézary syndrome (SS) subtypes of cutaneous T-cell lymphomas (MF/SS-CTCLs), an MF- or SS-specific measure of QoL does not exist.

Objective: The objective of this research was to develop and validate the first QoL instrument for MF/SS-CTCL using a patient-centered approach.

Methods: A conceptual framework for the MF/SS-CTCL QoL was developed through a literature review and interviews with key opinion leaders. Read More

View Article

Download full-text PDF

Source
https://www.jmir.org/2019/1/e11302/
Publisher Site
http://dx.doi.org/10.2196/11302DOI Listing
January 2019
7 Reads

SLAMF1/CD150 in hematologic malignancies: Silent marker or active player?

Clin Immunol 2018 Oct 25. Epub 2018 Oct 25.

Department of Molecular and Cellular Pathobiology, R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology National Academy of Sciences of Ukraine, Kyiv, Ukraine.

SLAMF1/CD150 receptor is a founder of signaling lymphocyte activation molecule (SLAM) family of cell-surface receptors. It is widely expressed on cells within hematopoietic system. In hematologic malignancies CD150 cell surface expression is restricted to cutaneous T-cell lymphomas, few types of B-cell non-Hodgkin's lymphoma, near half of cases of chronic lymphocytic leukemia, Hodgkin's lymphoma, and multiple myeloma. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S15216616183043
Publisher Site
http://dx.doi.org/10.1016/j.clim.2018.10.015DOI Listing
October 2018
4 Reads

Isolated cutaneous lymphomatous form of adult T-cell leukaemia/lymphoma.

Br J Haematol 2019 Jan 6. Epub 2019 Jan 6.

Department of Haematology, Hospital Clinic de Barcelona, IDIBAPS, Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15744DOI Listing
January 2019

The clinical value of imaging in primary cutaneous lymphomas: Role of high resolution ultrasound and PET-CT.

Br J Radiol 2019 Jan 4:20180904. Epub 2019 Jan 4.

4 Dermatology Service, Hospital Universitario, Puerta de Hierro, Majadahonda , Madrid , Spain.

Background:: Primary cutaneous lymphoma is a rare extranodal non-Hodgkin's lymphoma confined to the skin. The data on the imaging findings of primary cutaneous lymphomas are largely lacking and the current diagnosis is based on clinical and histopathological examination. With the advances in dermatological ultrasound and molecular imaging, newer perspectives in the evaluation of cutaneous lymphomas are available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1259/bjr.20180904DOI Listing
January 2019
8 Reads

Multiple remissions of extracavitary primary effusion lymphoma treated with a single cycle of liposomal doxorubicin in a patient infected with HIV.

Curr Oncol 2018 Dec 1;25(6):e592-e596. Epub 2018 Dec 1.

Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC.

Primary effusion lymphoma (pel) is a rare human herpesvirus 8 (hhv8)-related large B cell lymphoma with plasmablastic, immunoblastic, or anaplastic features that often carries a poor prognosis. This lymphoma occurs mainly in patients with hiv infection, most often with Epstein-Barr virus (ebv) co-infection, and usually presents as body cavity effusions or, less commonly, as extracavitary lesions without effusion (ec-pel). Chemotherapeutic treatment options are limited and require concurrent antiretroviral therapy (art). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.25.4119DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291272PMC
December 2018
1 Read

Primary cutaneous B-cell lymphoma: A single-center 5-year experience.

Indian J Cancer 2018 Apr-Jun;55(2):134-137

Department of Medical Oncology, Kidwai Cancer Institute, Bengaluru, Karnataka, India.

Background: Skin is the second most common site for extranodal non-Hodgkin's lymphoma (NHL). Most primary cutaneous NHLs are of T-cell origin (70%). Primary cutaneous B-cell lymphoma (PCBCL) is a rare entity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/ijc.IJC_418_17DOI Listing
January 2019
2 Reads

Adult-Onset Atopic Dermatitis.

J Allergy Clin Immunol Pract 2019 Jan;7(1):28-33

Departments of Dermatology, Preventive Medicine and Medical Social Sciences, Feinberg School of Medicine at Northwestern University, Chicago, Ill; Northwestern Medicine Multidisciplinary Eczema Center, Chicago, Ill. Electronic address:

One in 4 adults with atopic dermatitis (AD) report adult-onset disease. Adult-onset AD appears to be associated with a different disease phenotype compared with childhood-onset AD. A broad differential diagnosis must be considered in a patient presenting with an adult-onset eczematous eruption, including allergic contact dermatitis, mycosis fungoides/cutaneous T-cell lymphoma, psoriasis, scabies, and so forth. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2018.09.029DOI Listing
January 2019
1 Read

Utility of CD123 immunohistochemistry in differentiating lupus erythematosus from cutaneous T-cell lymphoma.

Histopathology 2018 Dec 31. Epub 2018 Dec 31.

Department of Pathology, University of Michigan, Ann Arbor, MI.

Aims: Histopathologic overlap between lupus erythematosus and certain types of cutaneous T-cell lymphoma (CTCL) is well documented. CD123+ plasmacytoid dendritic cells (PDCs) are typically increased in lupus erythematosus, but have not been well studied in CTCL. We aimed to compare CD123 immunostaining and histopathologic features in these conditions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13817DOI Listing
December 2018

CD30-positive cutaneous extranodal natural killer/T-cell lymphoma: clinicopathological features and survival outcomes.

Int J Dermatol 2018 Dec 30. Epub 2018 Dec 30.

Department of Dermatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Background: The prognostic value of CD30 expression in cutaneous extranodal natural killer/T-cell lymphoma is controversial.

Methods: Clinicopathological features, survival outcomes, and prognostic implications of CD30 were retrospectively analyzed in 55 patients with cutaneous extranodal natural killer/T-cell lymphoma. We classified patients into (i) primary cutaneous extranodal natural killer/T-cell lymphoma and (ii) cutaneous extranodal natural killer/T-cell lymphoma secondary to nasal disease depending on the primary tumor site. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14362DOI Listing
December 2018

Transplantation.

Authors:
Jasmine Zain

Cancer Treat Res 2019 ;176:269-287

City of Hope National Medical Center, Duarte, CA, USA.

Mature T-cell non-Hodgkin lymphomas (T-cell NHL) are a heterogeneous group of lymphoid malignancies including NK/T-cell lymphomas. Hematopoietic cell transplantation (HCT) is an important component of the management of T-cell NHL; however, the optimal timing and type of transplant for each different subtype is an ongoing debate. For the purpose of this chapter, PTCL will be classified as (1) systemic PTCL that includes nodal as well as non-nodal histologies in PTCL (2) CTCL-or cutaneous T-cell lymphomas that arise primarily in the skin and (3) NK/T-cell lymphomas both nasal and extranasal types. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/978-3-319-99716-2_13
Publisher Site
http://dx.doi.org/10.1007/978-3-319-99716-2_13DOI Listing
January 2019
9 Reads

CD30-Positive Lymphoproliferative Disorders.

Cancer Treat Res 2019 ;176:249-268

Division of Dermatology, City of Hope National Medical Center, Duarte, CA, USA.

Primary cutaneous CD30-positive lymphoproliferative disorders (CD30+ LPD) encompass lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (pcALCL), and borderline lesions [1]. CD30+ LPD are the second most common cutaneous T-cell lymphomas (CTCL) after mycosis fungoides (MF) and represent approximately 25% of all CTCL cases [2]. Their common phenotypic hallmark is an expression of the CD30 antigen, a cytokine receptor belonging to the tumor necrosis factor (TNF) receptor superfamily. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_12DOI Listing
January 2019

Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.

Cancer Treat Res 2019 ;176:225-248

Department of Hematology/Hematopoietic Cell Transplantation, Duarte, USA.

Mycosis fungoides and Sézary syndrome are the most common subtypes of all primary cutaneous lymphomas and represent complex diseases that require a multidisciplinary assessment by dermatologists, oncologists, and pathologists. Staging and work-up are critical to guarantee an optimal treatment plan that includes skin-directed and/or systemic regimens depending on the clinical stage, tumor burden, drug-related side effect profile, and patient comorbidities. However, there is no cure and patients frequently relapse, requiring repeated treatment courses for disease control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_11DOI Listing
January 2019
8 Reads

Rare T-Cell Subtypes.

Cancer Treat Res 2019 ;176:195-224

Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Australia.

There are a number of rare T-cell lymphoma subtypes that may be encountered in clinical practice. In recent years, improved immunohistochemical techniques and molecular tumor profiling have permitted refinement of some of the diagnostic categories in this group, as well as the recognition of distinct conditions not previously well elucidated. In this chapter, we cover the diagnostic and clinical features of some of the more common of these conditions, including subcutaneous panniculitis-like T-cell lymphoma, cutaneous gamma-delta T-cell lymphoma, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma, CD4-positive small/medium T-cell lymphoproliferative disorder, and acral CD8-positive T-cell lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_10DOI Listing
January 2019

Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.

Cancer Treat Res 2019 ;176:127-144

Department of Laboratory Medicine, University of Washington School of Medicine, 825 Eastlake Ave. East, P.O. Box G7-800, Seattle, WA, 98109, USA.

Anaplastic Large Cell Lymphomas (ALCL) are clinically aggressive and pathologically distinct lymphoid neoplasms that originate from a mature post-thymic T-cell. The contemporary World Health Organization (WHO) Classification of Haematologic Malignancies recognizes two distinct subtypes of systemic ALCL: Anaplastic Lymphoma Kinase (ALK)-negative, and ALK-positive. An additional unique subtype of ALCL is known to arise after prolonged exposure to breast implants, known as Breast Implant Associated ALCL (BIALCL). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_6DOI Listing
January 2019

Molecular and Genomic Landscape of Peripheral T-Cell Lymphoma.

Cancer Treat Res 2019 ;176:31-68

Department of Pathology, City of Hope National Medical Center, Duarte, CA, USA.

Peripheral T-cell lymphoma (PTCL) is an uncommon group of lymphoma covering a diverse spectrum of entities. Little was known regarding the molecular and genomic landscapes of these diseases until recently but the knowledge is still quite spotty with many rarer types of PTCL remain largely unexplored. In this chapter, the recent findings from gene expression profiling (GEP) studies, including profiling data on microRNA, where available, will be presented with emphasis on the implication on molecular diagnosis, prognostication, and the identification of new entities (PTCL-GATA3 and PTCL-TBX21) in the PTCL-NOS group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-319-99716-2_2DOI Listing
January 2019

Effects of SAHA and EGCG on Growth Potentiation of Triple-Negative Breast Cancer Cells.

Cancers (Basel) 2018 Dec 27;11(1). Epub 2018 Dec 27.

Department of Biology, University of Alabama at Birmingham, 1300 University Blvd, Birmingham, AL 35294, USA.

Triple-negative breast cancer comprises approximately 15⁻20% of all breast cancers diagnosed and is nearly twice as common in black women than white women in the United States. We evaluated the effects of two epigenetic-modifying compounds on markers of growth potential in several triple-negative breast cancer cell lines. Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase (HDAC) inhibitor currently used in the treatment of cutaneous T cell lymphoma, was administered to triple-negative breast cancer cells alone or in combination with epigallocatechin-3-gallate (EGCG), a DNA methyltransferase (DNMT) inhibitor isolated from green tea. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6694/11/1/23
Publisher Site
http://dx.doi.org/10.3390/cancers11010023DOI Listing
December 2018
1 Read

Cutaneous T-Cell Lymphoma: Trends in Radiation Doses and Patterns of Care 2004-2015.

Anticancer Res 2019 Jan;39(1):253-259

Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX, U.S.A.

Background And Aim: Radiotherapy is an effective treatment for cutaneous T-cell lymphoma (CTCL). Since 2009, studies have advocated for low-dose radiotherapy (<30 Gy) given it results in similar response rates and less toxicity compared to higher doses (≥30 Gy). We aimed to see if low-dose radiotherapy has been adopted on a national scale in the USA. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21873/anticanres.13105DOI Listing
January 2019

Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.

Eur J Dermatol 2018 Dec 27. Epub 2018 Dec 27.

Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, USA.

The efficacy of alemtuzumab for the treatment of refractory Sézary syndrome (SS) versus other third-line agents such as pralatrexate and gemcitabine is poorly characterized. To elucidate the effectiveness of alemtuzumab versus other third-line options for the treatment of refractory SS, we conducted a meta-analysis of existing data. A systematic review was performed in March 2017 based on a search using Ovid-MEDLINE and OVID-EMBASE for articles evaluating single-agent alemtuzumab, gemcitabine, or pralatrexate for the treatment of SS and mycosis fungoides (MF). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2018.3444DOI Listing
December 2018
1 Read

A Nodular Lesion of the Foot Detected by 18F-FDG PET/CT in Mycosis Fungoides: A Plantar Wart.

Clin Nucl Med 2018 Dec 26. Epub 2018 Dec 26.

From the Departments of Dermatology and.

A 34-year-old Japanese woman presented with widespread scaly erythema that had enlarged over 2 years. A skin biopsy revealed the diagnosis of mycosis fungoides (patch stage, T1b N0 M0 B0), a most frequent cutaneous T-cell lymphoma. F-FDG PET/CT scan unexpectedly showed intense uptake on the left sole, which suggested a tumorous mycosis fungoides lesion (SUVmax = 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002430DOI Listing
December 2018
5 Reads

Lymphoma or pseudolymphoma: A report of six cases and review of the literature.

Dermatol Ther 2018 Dec 27:e12807. Epub 2018 Dec 27.

Department of Dermatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

To explore and compare the clinical presentations and pathologic features of cutaneous pseudolymphomas (CPL) with primary cutaneous lymphomas. Review literature in order to improve the treatment of CPL. Six cases of CPLs were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12807DOI Listing
December 2018
2 Reads
1.478 Impact Factor

Low-Grade Cutaneous B-cell Lymphoma in African American Patients

J Drugs Dermatol 2018 Dec;17(12):1334 - 1337

Introduction: Cutaneous marginal zone lymphoma (CMZL) and cutaneous follicle center lymphoma (CFCL) are rare indolent cutaneous B-cell lymphomas (CBCL). Their incidence in African American (AA) patients is extremely low. While cutaneous T-cell lymphomas appear to be more aggressive in AA individuals, there is no data on the presentation and course of disease of CBCL in this group. Read More

View Article

Download full-text PDF

Source
December 2018
1 Read

Association of the POT1 Germline Missense Variant p.I78T With Familial Melanoma.

JAMA Dermatol 2018 Dec 26. Epub 2018 Dec 26.

Experimental Cancer Genetics, The Wellcome Trust Sanger Institute, Hinxton, England.

Importance: The protection of telomeres 1 protein (POT1) is a critical component of the shelterin complex, a multiple-protein machine that regulates telomere length and protects telomere ends. Germline variants in POT1 have been linked to familial melanoma, and somatic mutations are associated with a range of cancers including cutaneous T-cell lymphoma (CTCL).

Objective: To characterize pathogenic variation in POT1 in families with melanoma to inform clinical management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2018.3662DOI Listing
December 2018

EBV mucocutaneous ulcers in the setting of pre-existing cutaneous T-cell lymphoproliferative disorders: A report of 2 cases.

JAAD Case Rep 2019 Jan 11;5(1):78-81. Epub 2018 Dec 11.

Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2018.10.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6293026PMC
January 2019
2 Reads

Mycosis Fungoides Involving the Dorsal Tongue.

Case Rep Dermatol Med 2018 19;2018:5235246. Epub 2018 Nov 19.

Department of Dermatology, University of Texas McGovern Medical School at Houston, Houston, TX, USA.

Mycosis fungoides (MF) is a rare cutaneous T-cell lymphoma (CTCL) which can cause significant morbidity. During the disease course, it classically will progress through three clinical stages in the skin: patch-, plaque-, and tumor-stage. The early stages exhibit various histopathological mimics that often lead to misdiagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2018/5235246DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276500PMC
November 2018
4 Reads

[Primary cutaneous localization revealing leukemia/T-cell lymphoma associated with chronic HTLV-1 infection in a adult. A case presentation].

Ann Pathol 2018 Dec 18. Epub 2018 Dec 18.

Centre hospitalier universitaire Aristide le Dantec, service d'hématologie, avenue Pasteur, BP 3001, Dakar, Sénégal.

Adult T-cell leukemia/lymphoma (ATLL) is a rare medical condition and a diagnosis that ought to be considered for patients living in an area endemic for the HTLV-1 virus (human T-lymphotrophic virus) where a T-cell lymphoproliferative diagnosis has been made. The cutaneous clinical forms may be the first manifestation of the disease. We report here an observation in a 60-year-old Senegalese woman whose skin lesions were sampled to reveal the ATLL immunophenotypic profile CD4+, CD25+, FoxP3-, and CD7-. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annpat.2018.10.001DOI Listing
December 2018
1 Read

Post-thymic CD4 positive cytotoxic T cell infiltrates of the skin: A clinical and histomorphologic spectrum of the unique CD4 positive T cell of immunosenescence.

Ann Diagn Pathol 2018 Oct 27;38:99-105. Epub 2018 Oct 27.

Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.

T cell lymphoproliferative disorders that arise in the skin are mainly derived from post thymic T cells most commonly of CD4 subset. Human CD4 positive T cells are dynamic exhibiting phenotypic and functional malleability. For example, with repetitive antigen exposure most commonly associated with age, CD4 positive T cells acquire a cytotoxic phenotype. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S10929134183031
Publisher Site
http://dx.doi.org/10.1016/j.anndiagpath.2018.10.010DOI Listing
October 2018
5 Reads

Interferon alfa-2a maintenance after salvage autologous stem cell transplantation in atypical mycosis fungoides with central nervous system involvement.

Br J Dermatol 2018 Dec 18. Epub 2018 Dec 18.

Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland.

Mycosis fungoides is a primary cutaneous T-cell lymphoma with unfavorable prognosis for the advanced stages of the disease. Refractory disease and advanced-stage disease require systemic therapy. We report on a rare case of an atypical predominantly CD8+ folliculotropic mycosis fungoides (MF), a subtype of MF with poorer prognosis, in a 59-year-old woman, initially diagnosed with MF restricted to the skin- of T3N0M0B0/stage IIB according to the current WHO/EORTC classification. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bjd.17535
Publisher Site
http://dx.doi.org/10.1111/bjd.17535DOI Listing
December 2018
9 Reads

Enhanced Solubility, Permeability and Anticancer Activity of Vorinostat Using Tailored Mesoporous Silica Nanoparticles.

Pharmaceutics 2018 Dec 17;10(4). Epub 2018 Dec 17.

School of Pharmacy, The University of Queensland, Brisbane, QLD 4102, Australia.

Suberoylanilide hydroxamic acid (SAHA) or vorinostat (VOR) is a potent inhibitor of class I histone deacetylases (HDACs) that is approved for the treatment of cutaneous T-cell lymphoma. However, it has the intrinsic limitations of low water solubility and low permeability which reduces its clinical potential especially when given orally. Packaging of drugs within ordered mesoporous silica nanoparticles (MSNs) is an emerging strategy for increasing drug solubility and permeability of BCS (Biopharmaceutical Classification System) class II and IV drugs. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/1999-4923/10/4/283
Publisher Site
http://dx.doi.org/10.3390/pharmaceutics10040283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6321298PMC
December 2018
2 Reads

Merkel cell carcinoma arising in association with cutaneous T-cell lymphoma: A potential diagnostic pitfall.

J Cutan Pathol 2018 Dec 18. Epub 2018 Dec 18.

Department of Pathology, Michigan Medicine, Ann Arbor, Michigan.

Merkel cell carcinoma (MCC) is a rare, aggressive cutaneous neuroendocrine carcinoma with increased prevalence in patients with immunosuppression or B-cell neoplasms. To the best of our knowledge, an association with cutaneous T-cell lymphoma (CTCL) has not been previously described. In this report, we present two cases of MCC arising in the setting of CTCL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13404DOI Listing
December 2018
2 Reads

Double-positive CD8/CD4 primary cutaneous acral T-cell lymphoma.

J Cutan Pathol 2018 Dec 14. Epub 2018 Dec 14.

Department of Dermatology, Venerology and Allergology, University Medical Center Graz, Graz, Austria.

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/cup.13403
Publisher Site
http://dx.doi.org/10.1111/cup.13403DOI Listing
December 2018
3 Reads

Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases.

Dermatol Ther 2018 Dec 14:e12804. Epub 2018 Dec 14.

City of Hope Comprehensive Cancer Center, Cutaneous Lymphoma Program, Toni Stephenson Lymphoma Center, Duarte, California.

Cutaneous T-cell lymphomas (CTCL) are a relatively rare and heterogeneous group of non-Hodgkin lymphomas that typically present in the skin. The majority of patients with CTCL experience pruritus, which can interfere with daily activities, significantly impact quality of life, and is typically uncontrolled by standard anti-itch therapies. Several lymphoma treatments have reported anti-pruritic effects including romidepsin, a potent class 1 selective histone deacetylase inhibitor approved for the treatment of patients with CTCL who have had at least one prior systemic therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12804DOI Listing
December 2018
11 Reads

Canine non-epitheliotropic CD4-positive cutaneous T-cell lymphoma: a case report.

Vet Med Sci 2018 Dec 12. Epub 2018 Dec 12.

Synergy Animal General Hospital, Kawaguchi, Saitama, Japan.

A 5-year-old, spayed female French Bulldog presented with multiple papules on the skin of the scapular area. Histopathological examination of punch biopsy samples revealed dense infiltration of small lymphoid cells in the superficial dermis and in areas surrounding hair follicles. Immunohistochemical analysis indicated that these cells were positive for CD3, CD4, and TCRαβ, but negative for CD1c, CD8α, CD8β, CD11c, CD20, CD45RA, CD90, MHC-II, and TCRγδ. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/vms3.137DOI Listing
December 2018
4 Reads

Clinicopathological analysis of the hydroa vacciniforme-like lymphoproliferative disorder with natural killer cell phenotype compared with cutaneous natural killer T-cell lymphoma.

Exp Ther Med 2018 Dec 19;16(6):4772-4778. Epub 2018 Sep 19.

Department of Pathology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, P.R. China.

Hydroa vacciniforme-like lymphoproliferative disorder (HVLPD) is defined as a distinctive clinicopathological type of cutaneous lymphoma and a subset of patients with this disease exhibit the natural killer (NK)-cell phenotype. The HVLPD-NK cell phenotype may be difficult to distinguish from cutaneous natural killer T-cell lymphoma (CNKTL), as these two diseases share similar immunophenotypic markers. Therefore, the aim of the present study was to analyze the clinicopathological features of this rare disease and compare these features with those of CNKTL. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.6768DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257548PMC
December 2018

T cell-lymphoma in the eyelid of a 9-year-old English Setter.

Acta Vet Scand 2018 Dec 6;60(1):79. Epub 2018 Dec 6.

Eye Pathology Section, Department of Pathology, Rigshospitalet, Faculty of Health and Medical Sciences, University of Copenhagen, Frederik V's Vej, 11, 1st Floor, 2100, Copenhagen Ø, Denmark.

Background: Eyelid tumours are frequently found in dogs, most of these being benign. In case of an ulcerating eyelid tumour, malignancy must be considered. We report a unique case of a low-grade peripheral T-cell lymphoma in the eyelid of a 9-year-old English Setter. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13028-018-0432-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284267PMC
December 2018
2 Reads

[Recent advances in pediatric non-Hodgkin lymphoma. Report on a retrospective single-center cohort and review of the literature].

Magy Onkol 2018 Dec 15;62(4):204-213. Epub 2018 Oct 15.

Gyermekgyógyászati Intézet, Gyermekhematológiai-onkológiai nem önálló Tanszék, Debreceni Egyetem, Általános Orvostudományi Kar, Debrecen, Hungary.

Classification, staging and treatment response criteria of pediatric NHL have been revised. Long-term survival reaches ~90% at the expense of severe acute toxicities. The outcome of refractory and relapsed cases is poor. Read More

View Article

Download full-text PDF

Source
December 2018
3 Reads

[Discrasia linfoide epiteliotrópica de células T. Tratamiento con radiación ultravioleta].

Gac Med Mex 2018 ;154(Supp 2):S41-S49

Unidad de Fototerapia. Hospital General Dr. Manuel Gea González, Ciudad de México, México.

Introduction: T-cell lymphoid dyscrasia is a group of different, infrequent, epitheliotropic inflammatory dermatosis that precede cutaneous T-cell lymphomas. Treatment with ultraviolet radiation is safe and efficacious.

Objective: To describe responses to treatment, secondary effects and complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.24875/GMM.18004577DOI Listing
January 2018
1 Read

Leishmania infection: Misdiagnosis as cancer and tumor-promoting potential.

Acta Trop 2018 Dec 7. Epub 2018 Dec 7.

Université Côte d'Azur, Inserm, C3M, Nice Cedex 3, France. Electronic address:

Given the prevalence of cancer and leishmaniasis worldwide, the presence of these two pathologies in the same tissue sample may be merely fortuitous. The clinical outcome of both diseases is under the control of innate and adaptive immunity, and in both cases these progressive diseases are characterized by an impaired host Th1 response. As a consequence, the Th2 cytokine microenvironment occurring in progressive leishmaniasis may potentially promote tumor cell proliferation and vice versa. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0001706X183132
Publisher Site
http://dx.doi.org/10.1016/j.actatropica.2018.12.010DOI Listing
December 2018
13 Reads

Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.

Neoplasia 2019 Jan 4;21(1):82-92. Epub 2018 Dec 4.

Department of Dermatology, University of Wisconsin and the Middleton VA Medical Center, Madison, WI. Electronic address:

Advanced-stage cutaneous T-cell lymphoma (CTCL) is usually a fatal malignancy despite optimal use of currently available treatments. In this preclinical study of novel CTCL therapy, we performed in vitro and ex vivo experiments to determine the efficacy of combination treatment with a panel of BET bromodomain inhibitors (BETi) (JQ1, OTX015, CPI-0610, I-BET762) and HDAC inhibitors (HDACi) (SAHA/Vorinostat, Romidepsin). BETi/HDACi combinations were synergistic (combination index <1) against cell viability and induced G0/G1 cell cycle arrest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2018.11.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280696PMC
January 2019
1 Read

Total Skin Electron Beam Therapy for Mycosis Fungoides Revisited With Adjuvant Systemic Therapy.

Clin Lymphoma Myeloma Leuk 2018 Nov 17. Epub 2018 Nov 17.

Roswell Park Comprehensive Cancer Center, Buffalo, NY. Electronic address:

Background: Although standard-dose total skin electron beam therapy (TSEBT) has been thought to provide the greatest clinical benefit for mycosis fungoides, recent studies have shown that low-dose TSEBT may also provide high rates of disease control.

Materials And Methods: A retrospective chart review was conducted for patients receiving TSEBT for mycosis fungoides at a single institution from 2009 to 2017. Patients were evaluated for overall survival, progression-free survival, and duration of clinical benefit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2018.11.015DOI Listing
November 2018
1 Read

Brentuximab vedotin in T-cell lymphoma.

Expert Rev Hematol 2018 Dec 10. Epub 2018 Dec 10.

a Department of Haematology , Peter MacCallum Cancer Centre , Melbourne , Australia.

Introduction: Brentuximab vedotin is an antibody-drug conjugate, which combines a CD30 monoclonal antibody with the microtubule disrupting agent monomethylauristatin E. The utility of brentuximab vedotin has been explored in a number of diseases, with a recent focus on T-cell lymphoma, particularly systemic anaplastic large-cell lymphoma (sALCL) and cutaneous T-cell lymphoma (CTCL), as well as other peripheral T-cell lymphoma (PTCL) histologies. Areas covered: This review surveys current data on the efficacy of brentuximab vedotin in T-cell lymphoma, as well as embedding it in a therapeutic context by reviewing potential competitor agents in the clinic. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17474086.2019.1
Publisher Site
http://dx.doi.org/10.1080/17474086.2019.1558399DOI Listing
December 2018
2 Reads

Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature.

Chin Clin Oncol 2018 Nov 21. Epub 2018 Nov 21.

Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer and Weill Cornell Medical College, New York, NY, USA.

The vast majority of cutaneous T-cell lymphomas (CTCL) are encompassed by mycosis fungoides and CD30+ lymphoproliferative disorder (LPD), however rare distinct CTCLs have been defined. The current edition of the World Health Organization (WHO) includes 12 CTCL subtypes with discrete diagnosable clinical, histologic and phenotypic features. The rarest subtypes, i. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2018.11.01DOI Listing
November 2018
4 Reads

Sezary syndrome, recent biomarkers and new drugs.

Chin Clin Oncol 2018 Nov 28. Epub 2018 Nov 28.

Istituto Dermopatico dell' Immacolata, IDI-IRCCS, Rome, Italy.

Sezary syndrome (SS) is a primary cutaneous T-cell lymphoma (CTCL) characterized by erythroderma, lymphadenopathy and leukemic involvement of the peripheral blood. The high relapse rates and a poor prognosis complicate its clinical course and treatment. The phenotypic characterization and genomic/transcriptomic approaches revealed high heterogeneity of Sezary cells, identifying a wide spectrum of biomarkers implicated in the development of this lymphoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2018.11.02DOI Listing
November 2018